verapamil has been researched along with pargyline in 15 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 3 (20.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (6.67) | 29.6817 |
2010's | 9 (60.00) | 24.3611 |
2020's | 2 (13.33) | 2.80 |
Authors | Studies |
---|---|
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
Chen, J; Chen, X; Huang, L; Li, X; Sun, Y | 1 |
Huang, M; Jiang, N; Kong, LY; Lan, JS; Wang, XB; Xie, SS | 1 |
Jiang, N; Kong, LY; Lan, JS; Li, ZR; Wang, KD; Wang, X; Xie, SS; Yu, W | 1 |
Jiang, N; Kong, LY; Lan, JS; Li, F; Wang, J; Wang, X; Wang, ZM; Wu, JJ; Xie, SS | 1 |
Brazzolotto, X; Brus, B; Colletier, JP; Coquelle, N; Gobec, S; Knez, D; Kos, J; Košak, U; Nachon, F; Pišlar, A | 1 |
Cai, P; Kong, LY; Li, F; Liu, QH; Wang, J; Wang, XB; Wu, JJ; Yang, HL; Yang, XL | 1 |
Ding, Y; Hou, JW; Kang, P; Lan, JS; Liu, Y; Xie, SS; Zhang, T; Zhang, XY | 1 |
Cai, P; Fang, SQ; Kong, LY; Liu, QH; Tang, YW; Wang, C; Wang, XB; Yang, HL; Yang, XL | 1 |
Huang, M; Jiang, N; Kong, LY; Lan, JS; Wang, XB; Yin, FC | 1 |
Chan, CF; Chan, KF; Chan, TH; Chong, TC; Chow, LMC; Chow, TS; Cui, J; Law, MC; Liu, Z; Wong, ILK; Zhu, X | 1 |
Janssens, WJ; Vanhoutte, PM | 1 |
Carlsson, L; Graefe, KH; Trendelenburg, U | 1 |
Chaudhry, A; Vohra, MM | 1 |
Chen, B; Han, R; Li, JX; Liang, JH; Lu, Y; Wang, XH; Ye, XF; Zhang, P | 1 |
15 other study(ies) available for verapamil and pargyline
Article | Year |
---|---|
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Inhibition of cholinesterase and monoamine oxidase-B activity by Tacrine-Homoisoflavonoid hybrids.
Topics: Alzheimer Disease; Animals; Blood-Brain Barrier; Cholinesterase Inhibitors; Cholinesterases; Electrophorus; Humans; Isoflavones; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Swine; Tacrine | 2013 |
Multifunctional coumarin derivatives: monoamine oxidase B (MAO-B) inhibition, anti-β-amyloid (Aβ) aggregation and metal chelation properties against Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Binding Sites; Blood-Brain Barrier; Cell Line, Tumor; Cell Survival; Chelating Agents; Coumarins; Drug Design; Humans; Metals; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; PC12 Cells; Protein Structure, Tertiary; Rats | 2015 |
Multi-target tacrine-coumarin hybrids: cholinesterase and monoamine oxidase B inhibition properties against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Benzopyrans; Blood-Brain Barrier; Brain; Cell Survival; Cells, Cultured; Cholinesterase Inhibitors; Coumarins; Drug Design; Erythrocytes; Humans; Kinetics; Models, Molecular; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroblastoma; Piperazines; Tacrine | 2015 |
Design, synthesis and biological evaluation of novel donepezil-coumarin hybrids as multi-target agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Butyrylcholinesterase; Cell Line, Tumor; Cholinesterase Inhibitors; Cholinesterases; Coumarins; Donepezil; Dose-Response Relationship, Drug; Drug Design; Eels; Humans; Indans; Models, Molecular; Molecular Structure; Molecular Targeted Therapy; Piperidines; Structure-Activity Relationship | 2016 |
N-Propargylpiperidines with naphthalene-2-carboxamide or naphthalene-2-sulfonamide moieties: Potential multifunctional anti-Alzheimer's agents.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Butyrylcholinesterase; Cell Death; Cell Line; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Humans; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Naphthalenes; Peptide Fragments; Piperidines; Structure-Activity Relationship; Sulfonamides | 2017 |
Design, synthesis and evaluation of coumarin-pargyline hybrids as novel dual inhibitors of monoamine oxidases and amyloid-β aggregation for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Survival; Coumarins; Dose-Response Relationship, Drug; Drug Design; Humans; Male; Mice; Mice, Inbred Strains; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Pargyline; PC12 Cells; Protein Aggregates; Rats; Structure-Activity Relationship | 2017 |
Design, synthesis and biological evaluation of novel coumarin-N-benzyl pyridinium hybrids as multi-target agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Cholinesterase Inhibitors; Coumarins; Dose-Response Relationship, Drug; Drug Design; Humans; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; PC12 Cells; Protein Aggregates; Pyridinium Compounds; Rats; Structure-Activity Relationship | 2017 |
Design, synthesis, and evaluation of salicyladimine derivatives as multitarget-directed ligands against Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Survival; Dose-Response Relationship, Drug; Drug Design; Humans; Hydrogen Peroxide; Imines; Ligands; Lipopolysaccharides; Mice; Microglia; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; PC12 Cells; Peptide Fragments; Protein Aggregates; Rats; Salicylates; Structure-Activity Relationship | 2017 |
Chromone and donepezil hybrids as new multipotent cholinesterase and monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease.
Topics: | 2020 |
Flavonoid Monomers as Potent, Nontoxic, and Selective Modulators of the Breast Cancer Resistance Protein (ABCG2).
Topics: Antibodies, Monoclonal; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flavonoids; HEK293 Cells; Humans; Mitoxantrone; Neoplasm Proteins; Structure-Activity Relationship; Substrate Specificity | 2021 |
Instantaneous changes of alpha-adrenoceptor affinity caused by moderate cooling in canine cutaneous veins.
Topics: Animals; Biological Transport, Active; Body Temperature Regulation; Cold Temperature; Dogs; Estradiol; In Vitro Techniques; Muscle, Smooth; Norepinephrine; Ouabain; Pargyline; Phenoxybenzamine; Potassium; Receptors, Adrenergic; Receptors, Adrenergic, alpha; Skin; Skin Temperature; Sodium; Vasomotor System; Veins; Verapamil | 1978 |
Early intraneuronal mobilization and deamination of noradrenaline during global ischemia in the isolated perfused rat heart.
Topics: Animals; Calcium; Coronary Circulation; Coronary Disease; Deamination; Desipramine; Heart; In Vitro Techniques; Male; Mandelic Acids; Methoxyhydroxyphenylglycol; Neurons; Norepinephrine; Pargyline; Rats; Rats, Inbred Strains; Reserpine; Verapamil | 1987 |
Mechanism and metabolic disposition of verapamil-evoked overflow of radioactivity from isolated atria preloaded with [3H]norepinephrine.
Topics: Animals; Calcium; Cocaine; Heart Atria; In Vitro Techniques; Male; Myocardium; Norepinephrine; Pargyline; Rats; Rats, Inbred Strains; Reserpine; Tetrodotoxin; Verapamil | 1985 |
L-type calcium channel blockers enhance 5-HTP-induced antinociception in mice.
Topics: 5-Hydroxytryptophan; Analgesics; Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Chloride; Chelating Agents; Drug Synergism; Egtazic Acid; Female; Fluoxetine; Injections, Intraventricular; Mice; Motor Activity; Nifedipine; Nimodipine; Pain Measurement; Pargyline; Selective Serotonin Reuptake Inhibitors; Verapamil | 2004 |